Endo Health downgraded to Underperform from Sector Perform at RBC Capital RBC Capital downgraded Endo Health given valuation and concerns regarding the future of the Opana ER franchise due to potential future generics. Price target lowered to $24 from $25.
News For ENDP From The Last 14 Days
Check below for free stories on ENDP the last two weeks.
Endo shares remain overvalued, says Cantor Cantor Fitzgerald raised its priced target for Endo shares to $52 from $37 ahead of the company's Q2 results, but says the stock remains overvalued. The firm keeps a Sell rating on the name.